(R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST

• Main Authors: ROVATI, Lucio Claudio, MAKOVEC, Francesco, PUCCI, Sabrina
• Format: Patent
• Language: English; French
• Published: 16.01.2020
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

The following invention relates to (R)-4-(1-(1-(4-(trifluoromethyl)benzyl) pyrrodiline- 2-carboxamide) cyclopropyl benzoic acid (Compound 1) or a salt thereof. Advantageous methods for obtaining the Compound 1 are also described, as well as pharmaceutical compositions containing it. (R)-4-(1-(1-(4- (trifluoromethyl)benzyl)pyrrodiline-2-carboxamide) cyclopropyl benzoic acid (Compound 1) or a pharmaceutically acceptable salt thereof is described for use as an EP4 receptor antagonist in the treatment of a pathology that involves the activities of prostaglandin E2 (PGE2) in its pathogenesis. La présente invention concerne l'acide (R)-4-(1-(1-(4-(trifluorométhyl)benzyl) pyrrodiline- 2-carboxamide) cyclopropyl benzoïque (composé 1) ou un sel de celui-ci. L'invention concerne également des procédés avantageux permettant d'obtenir le composé 1, ainsi que des compositions pharmaceutiques le contenant. L'invention concerne l'acide (R)-4-(1-(1-(4- (trifluorométhyl)benzyl)pyrrodiline-2-carboxamide) cyclopropyl benzoïque (composé 1) ou un sel pharmaceutiquement acceptable de celui-ci pour une utilisation en tant qu'antagoniste du récepteur EP4 dans le traitement d'une pathologie qui implique les activités de la prostaglandine E2 (PGE2) dans sa pathogenèse.